Completed clinical trials have shown that FXI/FXIa inhibitors are safe and effective in preventing VTE and have broad application prospects, especially in patients with end-stage renal disease undergoing hemodialysis and those with TKA. This evidence concerns the gene F11 and chronic kidney disease.